Scholar Rock stock: Company reports $107.2 million Q3 net loss
Published on 11/20/2026 at 01:20 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSScholar Rock advances its commercial launch
- ISEMBYLD shipments and early patient infusions marked the first commercial phase for the SMA therapy.
- European and Japanese regulatory reviews are expected to shape the next international milestones.
- The company agreed to sell its priority review voucher for 205 million US dollars, subject to closing conditions.
Scholar Rock reported a third-quarter net loss of 107.2 million US dollars on November 10, as the biotechnology company began commercializing ISEMBYLD for spinal muscular atrophy. The company recorded 0.6 million US dollars in net product revenue for the quarter ended September 30, compared with no product revenue in the year-earlier period. The figures and business update were published in a Scholar Rock release.
Scholar Rock stock traded at 46.30 euros on Lang & Schwarz at 11:00 p.m. CET on Thursday, November 19. The company said ISEMBYLD shipments to the specialty network began before quarter-end, while initial patients were infused in October.
Regulatory milestones extend beyond America
The U.S. launch follows FDA approval on September 11 for adults and children aged two and older with SMA who receive an SMN2-targeted treatment. Scholar Rock said its European marketing application for apitegromab was resubmitted and validated in October, with a CHMP opinion expected in the first half of 2027.
In Japan, the company submitted an application for apitegromab that was accepted under priority review. Scholar Rock also said it is engaging with regulators on a subcutaneous formulation and is advancing Phase 2 studies in SMA and facioscapulohumeral muscular dystrophy.
Voucher sale strengthens funding position
Scholar Rock entered a definitive agreement in November to sell its Rare Pediatric Disease Priority Review Voucher for 205 million US dollars. The cash is due at closing, which remains subject to customary conditions including the applicable Hart-Scott-Rodino waiting period.
Biotechnology platform and pipeline
Scholar Rock is a U.S. biopharmaceutical company headquartered in Cambridge, Massachusetts. It develops therapies for rare neuromuscular diseases by targeting protein growth factor signaling, with ISEMBYLD as its lead commercial product and additional programs in SMA, muscle disease and oncology. Its pipeline includes apitegromab programs and the investigational SRK-439 myostatin inhibitor, while the company also collaborates with Gilead Sciences on targeted inhibitors for fibrotic diseases.
Scholar Rock at a glance
- Company: Scholar Rock Holding Corporation
- Ticker: SRRK
- Sector: Healthcare
- Industry: Biotechnology
- Headquarters: Cambridge, Massachusetts, United States
- Lang & Schwarz quote: 46.30 euros at 11:00 p.m. CET on Thursday, November 19, 2026
Scholar Rock operates within the U.S. market environment tracked by the S&P 500.
